Authors: Ketter, et al.
Title: Open-label maintenance treatment for bipolar depression using olanzapine or olanzapine/fluoxetine combination.
Reference: World J Psychiatry 2004;5(Suppl 1):51. [Congress abstract]
Purpose: Assessment of olanzapine and OFC for 6-month maintenence in subjects who achieved remission of depressive symptoms after acute treatment.
Study design: Non-comparative, open-label extension trial.
Follow up: 6 months.
Patients: 192 patients.
Treatment: Olanzapine 5–20 mg/day or OFC (dosage not stated) as needed.
Results: 62.5% of patients remained free from relapse at 6 months. The median time to relapse for those that relapsed was 194 days.